MacroGenics, Inc. Stock News

ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:

MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants James Karrels - Senior Vice President, Chief Financial Officer and Secretary Scott Koenig - President and Chief Executive Officer Conference Call Participants Nicholas Lorusso - TD Cowen Jonathan Chang - Leerink Partners Reena Patel - Citi Etzer Darout - BMO Capital Markets Jonatha...

ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2024.

ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board ...

ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGen...

WILMINGTON, DE / ACCESSWIRE / October 25, 2024 / Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ GS:MGNX) on behalf of stockholders.

ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX).